Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting

Core Insights - Ascletis Pharma Inc. is set to present data from its Phase Ib clinical study of the oral GLP-1 receptor agonist ASC30 at the 61st EASD Annual Meeting in Vienna, Austria [1][2] - The company is on track to report topline data from a Phase IIa clinical study of ASC30 in participants with obesity or overweight by the fourth quarter of 2025 [1] Group 1: Clinical Study and Presentation - The 28-day multiple ascending dose study of ASC30 demonstrated superior weight loss in participants with obesity [2] - The short oral discussion will take place on September 16, 2025, from 12:00 to 13:00 CEST, with presentation number 827 [2] Group 2: Product Information - ASC30 is a new chemical entity (NCE) with unique properties allowing for both oral tablet and subcutaneous injection administration, protected by U.S. and global patents until 2044 [3] Group 3: Company Overview - Ascletis Pharma Inc. focuses on developing and commercializing therapeutics for metabolic diseases, utilizing its proprietary AI-assisted drug discovery platform [5] - The company is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [5]